NOTICE: Due to a lapse in annual appropriations, most of this website is not being updated. Learn more.
Form submissions will still be accepted but will not receive responses at this time. Sections of this site for programs using non-appropriated funds (such as NVLAP) or those that are excepted from the shutdown (such as CHIPS and NVD) will continue to be updated.
An official website of the United States government
Here’s how you know
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Important consideration when expressing mAbs in Escherichia coli
Published
Author(s)
William Siegall, Zvi Kelman
Abstract
Monoclonal antibodies (mAbs) are a driving force in the biopharmaceutical industry. The production of therapeutic mAbs is primarily done in mammalian cells, but recently there has been a push towards the use of alternative production hosts including Escherichia coli. When the genes encoding for the mAbs heavy and light chains are codon-optimized for E. coli expression it has been noted that a truncated form of the heavy chain can be formed along with the full-length product. Here, the observation of the factors that lead to a truncated product was expended to several therapeutic mAbs and optimization algorithms. Approaches to avoid this truncated form are discussed.
Siegall, W.
and Kelman, Z.
(2024),
Important consideration when expressing mAbs in Escherichia coli, Protein Expression and Purification, [online], https://doi.org/10.1016/j.pep.2024.106499, https://tsapps.nist.gov/publication/get_pdf.cfm?pub_id=936482
(Accessed October 9, 2025)